Remimazolam versus sevofulrane for transcatheter aortic valve implantation; a randomized open label trial

Remimazolam versus sevofulrane for transcatheter aortic valve implantation; a randomized open label trial - Remimazolam versus sevofulrane for TAVI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000047892

Enrollment

Registered

2022-06-01

Start date

2022-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe aortic stenosis

Interventions

Using remimazolam as a sedative for general anesthesia Using sevoflurane and midazolam as sedatives for general anesthesia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Severe aortic stenosis

Exclusion criteria

Exclusion criteria: 1. Allergic to remimazolam, sevoflurane, midazolam, or flumazenil 2. Past history or family history of malignant hyperthermia 3. Patients with difficulties for participation due to psychologic conditions 4. Patients who are not considered to be feasible

Design outcomes

Primary

Measure	Time frame
Emergence time from general anesthesia (time between cessation of anesthetics and extubation)	—

Secondary

Measure	Time frame
1. Blood pressure, heart rate, SpO2 during general anesthesia 2. Doses of vasopressors during general anesthesia 3. Intra- and post-operative comprications 4. Respond to verbal stimuli, recovery of muscle strength (tidal volume, and strong hand grip)	—

Countries

Japan

Contacts

Public ContactKohei Godai

Kagoshima University Department of Anesthesiology

kouhei84@m2.kufm.kagoshima-u.ac.jp0992755430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026